000132809 001__ 132809
000132809 005__ 20250116144525.0
000132809 0247_ $$2doi$$a10.1210/clinem/dgae110
000132809 0248_ $$2sideral$$a137711
000132809 037__ $$aART-2024-137711
000132809 041__ $$aeng
000132809 100__ $$0(orcid)0000-0003-3963-0846$$aLaclaustra, Martin$$uUniversidad de Zaragoza
000132809 245__ $$aHigher Parametric Thyroid Feedback Quantile-based Index is a predictor of type 2 diabetes in a German population sample
000132809 260__ $$c2024
000132809 5060_ $$aAccess copy available to the general public$$fUnrestricted
000132809 5203_ $$aBackground
Type 2 diabetes has been described to be associated with hypothyroidism but we recently found that a decrease in pituitary sensitivity to thyroid hormone is associated with diabetes, obesity, and the metabolic syndrome. We aim to assess the longitudinal nature of this association in the population-based Study of Health in Pomerania(SHIP) in Germany.
Materials and Method
77% of a population-based sample of 4308 participants between 20 and 79 years was followed for 5 years. We studied 2542 participants without diabetes or thyroid medication at baseline and complete data in the variables of interest. Data of baseline thyroxine(fT4) and thyrotropin(TSH) were used to calculate the Parametric Thyroid Feedback Quantile-based Index(PTFQI), which measures whether TSH remains elevated despite fT4 being high. It uses the average population response as reference. PTFQI association with incidence of type 2 diabetes over 5 years was estimated with Poisson regression models adjusted for age, sex, and body mass index(BMI).
Results
Compared with the 1st PTFQI quartile, Incidence Rate Ratios (IRR) for diabetes were 1.54(95% CI 0.97 to 2.46), 1.55(0.94 to 2.57), and 1.97(1.27 to 3.10) for the upper quartiles (p-trend=0.004) after adjusting for age and sex. The association remained statistically significant after additionally adjusting for BMI: 1.64(1.05 to 2.59) for the 4th vs the 1st quartile (p-trend=0.043).
Conclusions
An elevation of the pituitary TSH-inhibition threshold is associated with incident type 2 diabetes independently of BMI. The PTFQI might have clinical potential for prognosis and metabolic status monitoring.
000132809 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI19-00020
000132809 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000132809 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000132809 700__ $$0(orcid)0000-0001-7431-0376$$aAlonso-Ventura, Vanesa$$uUniversidad de Zaragoza
000132809 700__ $$aSchipf, Sabine
000132809 700__ $$0(orcid)0000-0001-9578-6525$$aLou-Bonafonte, Jose Manuel$$uUniversidad de Zaragoza
000132809 700__ $$aDörr, Marcus
000132809 700__ $$aTrincado-Aznar, Pablo
000132809 700__ $$aVölzke, Henry
000132809 700__ $$aNauck, Matthias
000132809 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, Fernando$$uUniversidad de Zaragoza
000132809 700__ $$aIttermann, Till
000132809 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000132809 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000132809 773__ $$g109, 12 (2024), e2205–e2213$$pJ. clin. endocrinol. metab.$$tJOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM$$x0021-972X
000132809 8564_ $$s639000$$uhttps://zaguan.unizar.es/record/132809/files/texto_completo.pdf$$yPostprint$$zinfo:eu-repo/semantics/openAccess
000132809 8564_ $$s1000594$$uhttps://zaguan.unizar.es/record/132809/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint$$zinfo:eu-repo/semantics/openAccess
000132809 909CO $$ooai:zaguan.unizar.es:132809$$particulos$$pdriver
000132809 951__ $$a2025-01-16-14:42:55
000132809 980__ $$aARTICLE